Clinical trials: Thyroid Disease
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
- Trial name
- NCT06727604
- Testing
- IMVT-1402
- Where
- 134 sites in United States, Belgium and 8 more
- Volunteers
- 240 people
- Sponsor
- Immunovant Sciences GmbH
Anaplastic Thyroid Cancer
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects…
- Trial name
- FACT2 (NCT01701349)
- Testing
- Fosbretabulin + paclitaxel + carboplatin
- Sponsor
- Mateon Therapeutics
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Eye Disease
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease.
- Trial name
- NCT06525506
- Testing
- IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Eye Disease
A Study of IBI3031 in Participants With Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of…
- Trial name
- NCT07622368
- Testing
- IBI3031
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroiditis, Autoimmune
Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)
This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.
- Trial name
- ASAP (NCT01551498)
- Testing
- Anatabloc Supplement
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Thyroid Eye Disease
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-2 (NCT06106828)
- Testing
- Satralizumab
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Multiple System Atrophy
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass…
- Trial name
- NCT07238062
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Obesity, Lipid Disorders
A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers
This is a clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYT1, following oral administrations in healthy volunteers. The study shall be divided into four plans as given below: 1.
- Trial name
- NCT01543269
- Testing
- ZYT1
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Thyroid-Related Eye Disease
Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)
This is a pilot study to determine the safety and efficacy of orbital injections of LIPO-102.
- Trial name
- NCT00954057
- Testing
- LIPO-102
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 11 people
- Sponsor
- Neothetics, Inc
Hypothyroidism
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in…
- Trial name
- NCT05823012
- Testing
- levothyroxine sodium
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Xeris Pharmaceuticals
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue…
- Trial name
- NCT04204928
- Testing
- pralsetinib (BLU-667)
- Sponsor
- Blueprint Medicines Corporation
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Benign Thyroid Nodules
Treatment of Benign Thyroid Nodules With FastScan HIFU
This study evaluates the efficacy of the HIFU for the treatment of benign thyroid nodules with the FastScan version using assessment of patient experience and adverse event reporting.
- Trial name
- NCT02491502
- Testing
- Echopulse
- Where
- Bulgaria
- Volunteers
- 36 people
- Sponsor
- Theraclion
Advanced Solid Tumor
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1201 in subjects with advanced solid tumors.
- Trial name
- NCT05785728
- Testing
- DB-1202
- Where
- China
- Volunteers
- 150 people
- Sponsor
- DualityBio Inc.
Differentiated Thyroid Cancer
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects.
- Trial name
- NCT05745363
- Testing
- AL2846 capsule
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd